Oncology shifts to combos, precision care

Executives said one of the biggest challenges is understanding why some patients respond to treatment while others do not.

'The Next Oncology Wave: Where Value Wins and Only the Fittest Survive' Panelists / USAIC

Boston, April 30: The next wave of cancer treatment will depend less on single “blockbuster” drugs and more on precise combinations tailored to individual patients, as scientists confront the growing complexity and adaptability of tumours, industry leaders said at a high-level panel.

At the USA–India Chamber of Commerce’s BioPharma & Healthcare Summit, executives and researchers said the future of oncology lies in integrating biology, data science and new therapeutic modalities to deliver durable responses — and ultimately, longer survival.

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login